Comparative analysis of peptide nucleic acid (PNA)-mediated real-time PCR clamping and DNA direct sequencing for EGFR mutation detection

Tuberculosis and Respiratory Diseases

Volumn 70, Issue 1, 2011, Pages 21-27

  Kim, Hee Joung ^a   Kim, Wan Seop ^a   Shin, Kyeong Cheol ^b   Lee, Gwan Ho ^b   Kim, Mi Jin ^b   Lee, Jeong Eun ^c   Song, Kyu Sang ^c   Kim, Sun Young ^c   Lee, Kye Young ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

Author keywords

Epidermal growth factor; Molecular sequencing data; Peptide nucleic acids; Receptor, epidermal growth factor

Indexed keywords

GENOMIC DNA; PEPTIDE NUCLEIC ACID; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ARTICLE; DNA EXTRACTION; DNA SEQUENCE; EXON; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KOREA; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79952206708     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2011.70.1.21     Document Type: Article

References (23)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. (Pubitemid 34438899)
2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70. (Pubitemid 32963812)
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
4. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11. (Pubitemid 39209661)
6. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
8. Eberhard DA, Giaccone G, Johnson BE; Non-Small-Cell Lung Cancer Working Group. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-94. (Pubitemid 351398092)
9. Jänne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006;12:751-8. (Pubitemid 43259854)
10. Chin TM, Anuar D, Soo R, Salto-Tellez M, Li WQ, Ahmad B, et al. Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 2007;53:62-70. (Pubitemid 46047764)
11. Hoshi K, Takakura H, Mitani Y, Tatsumi K, Momiyama N, Ichikawa Y, et al. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 2007;13:4974-83. (Pubitemid 47502061)
12. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-82. (Pubitemid 41161259)
13. Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007;98:246-52. (Pubitemid 44941878)
14. Nielsen PE, Egholm M. An introduction to peptide nucleic acid. Curr Issues Mol Biol 1999;1:89-104.
15. Lee KY, Kim HJ, Kim SJ, Yoo GH, Kim WD, Oh SY, et al. PNA-mediated PCR clamping for the detection of EGFR mutations in non-small cell lung cancer. Tuberc Respir Dis 2010;69:271-8.
16. Hwang TS. Molecular biologic techniques in cytopathologic diagnosis. Korean J Pathol 2009;43:387-92.
17. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010;16:291-303.
18. Neal JW, Sequist LV. Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nat Rev Clin Oncol 2010;7:71-2.
19. Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 2010;22:112-20.
20. Choi J, Cho M, Oh M, Kim H, Kil MS, Park H. PNA-mediated real-time PCR clamping for detection of EGFR mutations. Bull Korean Chem Soc 2010;31:3525-9.
21. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
22. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 2008;3:527-9. (Pubitemid 351630282)
23. Wang J, Ramakrishnan R, Tang Z, Fan W, Kluge A, Dowlati A, et al. Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clin Chem 2010;56:623-32.